NYSE:USPH

U.S. Physical Therapy Stock Forecast, Price & News

$118.16
-0.07 (-0.06 %)
(As of 07/30/2021 04:42 PM ET)
Add
Compare
Today's Range
$116.83
$119.19
50-Day Range
$101.81
$121.37
52-Week Range
$74.79
$143.67
Volume32,984 shs
Average Volume67,827 shs
Market Capitalization$1.52 billion
P/E Ratio47.45
Dividend Yield1.18%
Beta1.46
30 days | 90 days | 365 days | Advanced Chart
Receive USPH News and Ratings via Email

Sign-up to receive the latest news and ratings for U.S. Physical Therapy and its competitors with MarketBeat's FREE daily newsletter.


U.S. Physical Therapy logo

About U.S. Physical Therapy

U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The company provides industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. As of December 31, 2020, it operated 544 outpatient physical therapy clinics in 39 states; and managed 38 physical therapy facilities. The company was founded in 1990 and is based in Houston, Texas.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

140th out of 2,216 stocks

Health Services Industry

1st out of 21 stocks

Analyst Opinion: 2.5Community Rank: 2.9Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











U.S. Physical Therapy (NYSE:USPH) Frequently Asked Questions

Is U.S. Physical Therapy a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for U.S. Physical Therapy in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" U.S. Physical Therapy stock.
View analyst ratings for U.S. Physical Therapy
or view top-rated stocks.

What stocks does MarketBeat like better than U.S. Physical Therapy?

Wall Street analysts have given U.S. Physical Therapy a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but U.S. Physical Therapy wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is U.S. Physical Therapy's next earnings date?

U.S. Physical Therapy is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for U.S. Physical Therapy
.

How can I listen to U.S. Physical Therapy's earnings call?

U.S. Physical Therapy will be holding an earnings conference call on Thursday, August 5th at 10:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were U.S. Physical Therapy's earnings last quarter?

U.S. Physical Therapy, Inc. (NYSE:USPH) released its quarterly earnings results on Thursday, May, 6th. The company reported $0.64 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.47 by $0.17. The firm had revenue of $112.37 million for the quarter, compared to analyst estimates of $110.36 million. U.S. Physical Therapy had a trailing twelve-month return on equity of 14.19% and a net margin of 7.73%. The company's quarterly revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.30 earnings per share.
View U.S. Physical Therapy's earnings history
.

How has U.S. Physical Therapy's stock price been impacted by COVID-19 (Coronavirus)?

U.S. Physical Therapy's stock was trading at $93.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, USPH shares have increased by 26.3% and is now trading at $117.74.
View which stocks have been most impacted by COVID-19
.

How often does U.S. Physical Therapy pay dividends? What is the dividend yield for U.S. Physical Therapy?

U.S. Physical Therapy declared a quarterly dividend on Thursday, May 6th. Shareholders of record on Friday, May 14th will be paid a dividend of $0.35 per share on Friday, June 11th. This represents a $1.40 annualized dividend and a dividend yield of 1.19%. The ex-dividend date of this dividend is Thursday, May 13th.
View U.S. Physical Therapy's dividend history
.

Is U.S. Physical Therapy a good dividend stock?

U.S. Physical Therapy pays an annual dividend of $1.40 per share and currently has a dividend yield of 1.20%. U.S. Physical Therapy does not yet have a strong track record of dividend growth. The dividend payout ratio of U.S. Physical Therapy is 46.82%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, U.S. Physical Therapy will have a dividend payout ratio of 46.98% next year. This indicates that U.S. Physical Therapy will be able to sustain or increase its dividend.
View U.S. Physical Therapy's dividend history.

What guidance has U.S. Physical Therapy issued on next quarter's earnings?

U.S. Physical Therapy updated its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share guidance of 2.680-2.780 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.56. The company issued revenue guidance of -.

What price target have analysts set for USPH?

2 analysts have issued 12 month target prices for U.S. Physical Therapy's shares. Their forecasts range from $130.00 to $135.00. On average, they anticipate U.S. Physical Therapy's share price to reach $132.50 in the next year. This suggests a possible upside of 12.5% from the stock's current price.
View analysts' price targets for U.S. Physical Therapy
or view top-rated stocks among Wall Street analysts.

Who are U.S. Physical Therapy's key executives?

U.S. Physical Therapy's management team includes the following people:
  • Mr. Christopher J. Reading, Pres, CEO & Director (Age 57, Pay $1.43M)
  • Mr. Carey P. Hendrickson, Chief Financial Officer (Age 59, Pay $384.46k)
  • Mr. Glenn D. McDowell, Chief Operating Officer of West (Age 64, Pay $874.52k)
  • Mr. Graham D. Reeve M.B.A., P.T., Chief Operating Officer of East (Age 57, Pay $911.94k)
  • Mr. Richard S. Binstein, Gen. Counsel & Sec.
  • Mr. Jon C. Bates, VP & Corp. Controller
  • Johnny J. Blanchard, Assistant Controller

What is Chris Reading's approval rating as U.S. Physical Therapy's CEO?

38 employees have rated U.S. Physical Therapy CEO Chris Reading on Glassdoor.com. Chris Reading has an approval rating of 49% among U.S. Physical Therapy's employees. This puts Chris Reading in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of U.S. Physical Therapy's key competitors?

What other stocks do shareholders of U.S. Physical Therapy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other U.S. Physical Therapy investors own include Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), International Business Machines (IBM), Illumina (ILMN), Johnson & Johnson (JNJ), Lowe's Companies (LOW) and Marathon Petroleum (MPC).

What is U.S. Physical Therapy's stock symbol?

U.S. Physical Therapy trades on the New York Stock Exchange (NYSE) under the ticker symbol "USPH."

Who are U.S. Physical Therapy's major shareholders?

U.S. Physical Therapy's stock is owned by many different retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.74%), Aptus Capital Advisors LLC (0.14%), State of Alaska Department of Revenue (0.07%) and Albert D Mason Inc. (0.05%). Company insiders that own U.S. Physical Therapy stock include Bernard A Harris Jr, Bernard A Harris, Jr, Christopher J Reading, Clayton Trier, Edward L Kuntz, Glenn Mcdowell, Graham D Reeve, Harry S Chapman, Kathleen A Gilmartin, Lawrance W Mcafee, Mark J Brookner and Regg E Swanson.
View institutional ownership trends for U.S. Physical Therapy
.

Which institutional investors are selling U.S. Physical Therapy stock?

USPH stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., and Albert D Mason Inc.. Company insiders that have sold U.S. Physical Therapy company stock in the last year include Bernard A Harris Jr, Bernard A Harris, Jr, Christopher J Reading, Edward L Kuntz, Graham D Reeve, Harry S Chapman, Lawrance W Mcafee, and Mark J Brookner.
View insider buying and selling activity for U.S. Physical Therapy
or view top insider-selling stocks.

Which institutional investors are buying U.S. Physical Therapy stock?

USPH stock was bought by a variety of institutional investors in the last quarter, including Aptus Capital Advisors LLC, and State of Alaska Department of Revenue. Company insiders that have bought U.S. Physical Therapy stock in the last two years include Harry S Chapman, Kathleen A Gilmartin, and Regg E Swanson.
View insider buying and selling activity for U.S. Physical Therapy
or or view top insider-buying stocks.

How do I buy shares of U.S. Physical Therapy?

Shares of USPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is U.S. Physical Therapy's stock price today?

One share of USPH stock can currently be purchased for approximately $117.74.

How much money does U.S. Physical Therapy make?

U.S. Physical Therapy has a market capitalization of $1.52 billion and generates $422.97 million in revenue each year. The company earns $35.19 million in net income (profit) each year or $2.99 on an earnings per share basis.

How many employees does U.S. Physical Therapy have?

U.S. Physical Therapy employs 4,630 workers across the globe.

What is U.S. Physical Therapy's official website?

The official website for U.S. Physical Therapy is www.usph.com.

Where are U.S. Physical Therapy's headquarters?

U.S. Physical Therapy is headquartered at 1300 WEST SAM HOUSTON PARKWAY SUITE 300, HOUSTON TX, 77042.

How can I contact U.S. Physical Therapy?

U.S. Physical Therapy's mailing address is 1300 WEST SAM HOUSTON PARKWAY SUITE 300, HOUSTON TX, 77042. The company can be reached via phone at 713-297-7000 or via email at [email protected]


This page was last updated on 7/30/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.